focus -WSS

focus

author：hotspot 2025-09-30 18:00:46 - browse：384

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Leon Gautier, last member of French D

entertainment

WSS

An interview with Robert F. Kennedy Jr. on vaccines

Living with Hashimoto's and celiac disease, and med school, too

An interview with Robert F. Kennedy Jr. on vaccines

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

entertainment

focus

hotspot

New air purifier tech could be key to improving indoor air quality

Listen: Racing for gene therapy & a pioneering approval

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

State Dept. review finds Biden bears some blame for Afghanistan failures

Clinical trials must include more disabled people

Hepatitis C has a cure — but many Americans still lack access to it

Hilary may become 1st tropical storm to make landfall in California in 84 years

The high cost of giving birth even with insurance

3 killed, 8 injured in late

knowledge

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Some in Scotland's Orkney Islands want to return to Norway after 550 years

FDA approves first treatment for ultra

US judge blocks portions of new Florida elections law

Greece's new parliament sworn in following conservative party's election victory

Patient advocates sound warning on FDA proposal on salt intake

entertainment

entertainment

focus

hotspot